(formerly DQTC-SOS Reports)

The Committee to Evaluate Drugs/CCO Subcommittee (CED-CCO) reports are systematically developed statements aimed to assist deliberations of the CED, the committee responsible for making recommendations regarding drug funding. In contrast to clinical practice and organizational guidelines, the CED-CCO reports (formerly termed the Drug Quality Therapeutic Committee’s Standing Oncology Subcommittee (DQTC-SOS) Reports) have not completed the full guideline development cycle.

The PEBC developed the following evidence-based reports in response to requests from the CCO-CED and the DQTC-SOS.

• Zoledronic acid for the treatment of bone metastases secondary to renal cell carcinoma
  CED-CCO Special Advice Report #18: June 16, 2010
  • Summary
  • Summary and Full Report

• The Role of Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer
  DQTC-SOS Advice Report #1: April 2005
  • Summary
  • Summary and Full Report
• The Role of Porfimer Sodium (Photofrin™) in the Ablation of High-Grade Dysplasia Associated with Barrett’s Esophagus
  DQTC-SOS Advice Report #2.version 2: June 2006
  • Summary
  • Summary and Full Report
• The Role of Porfimer Sodium (Photofrin™) in the Palliative Treatment of Esophageal Cancer
  DQTC-SOS Advice Report #3: January 2006
  • Summary
  • Summary and Full Report
• Alemtuzumab for the Treatment of T-cell Prolymphocytic Leukemia
  CED-CCO Advice Report 6-22: January 2007
  • Summary
  • Summary and Full Report
• The Role of Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
  CED-CCO Advice Report #4: May 2007
  • Summary
  • Summary and Full Report
• Recombinant Humanized Thyroid Stimulating Hormone (rhTSH) Preparation Prior To Radioiodine Ablation in Patients Who Have Undergone Thyroidectomy for Papillary or Follicular Thyroid Cancer
  CED-CCO Advice Report #5: May 2007
  • Practice Guideline
  • Evidence-Based Guideline
    
• Dasatinib for the Treatment of Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia
  CED-CCO Advice Report 6-23: June 2007
  • Summary
  • Summary and Full Report
• The Role of Albumin-bound Paclitaxel (Abraxane) in the Treatment of Metastatic Breast Cancer
  CED-CCO Advice Report #6: June 2007
  • Practice Guideline
  • Evidence-Based Series
• Sorafenib for Advanced Hepatocellular Carcinoma
  CED-CCO Advice Report #7: February 2008
  • Evidence-Based Series
• The Use of Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer
  CED-CCO Advice Report #8: July 2008
  • Evidence-Based Series
• Docetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer
  CED-CCO Advice Report #9: September 2008
  • Evidence-Based Series
• The Use of Imatinib Mesylate (Gleevec ^TM ) in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  CED-CCO Advice Report #10: September 2008
  • Evidence-Based Series
• Bortezomib in Multiple Myeloma and Lymphoma
  CED-CCO Advice Report #11: November 2008
  • Summary
  • Summary and Full Report
  
  The evidence in this report is more up-to-date than Evidence-based Series (EBS) #6-18 Bortezomib in multiple myeloma and lymphoma. As always, the advice report has not undergone the same rigorous guideline development process as an EBS. EBS #6-18 is currently being updated to incorporate the evidence within the advice report and will be available in late in 2009
• The Use of Bevacizumab in Metastatic Breast Cancer
  CED-CCO Advice Report #12: April 2009
  
  • Summary
  • Summary and Full Report
• The Continued Use of Trastuzumab Beyond Disease Progression in Patients with Metastatic Breast Cancer
  CED-CCO Advice Report #13: August 2009
  
  • Summary
  • Summary and Full Report
• The Prophylactic Use of Filgrastim in Patients with Hematological Malignancies
  CED-CCO Advice Report #14-1: September 23, 2009
  
  • Summary
  • Summary and Full Report
• The Prophylactic Use of Filgrastim in Patients with Breast Cancer
  CED-CCO Advice Report #14-2: October 1, 2009
  
  • Summary
  • Summary and Full Report
• Rituximab in Chronic Lymphocytic Leukemia
  CED-CCO Special Advice Report #15: November 18, 2009
  
  • Summary
  • Summary and Full Report
• Zoledronic Acid Adjuvant Therapy in Combination with Adjuvant Endocrine Therapy for Premenopausal Women with Early-Stage Hormone Receptor Positive Breast Cancer
  CED-CCO Advice Report #16: January 25, 2010
  
  • Summary
  • Summary and Full Report
• Imatnib Mesylate in the Adjuvant Treatment of Gastrointestinal Stromal Tumours (GIST)
  CED-CCO Special Advice Report #17: May 31, 2010
  
  • Summary
  • Summary and Full Report